Home › Funds › ACUTA CAPITAL PARTNERS, LLC › TSHA

ACUTA CAPITAL PARTNERS, LLC position in TSHA

TAYSHA GENE THERAPIES INC · Health Care

ACUTA CAPITAL PARTNERS, LLC reported holding 561,808 shares of TSHA (TAYSHA GENE THERAPIES INC) in its Q2 2026 13F filing — a position valued at US$3.8M, representing 2.67% of its reported portfolio and ranking #15 among its reported holdings. ACUTA CAPITAL PARTNERS, LLC has disclosed TSHA holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)561.81K sh
Reported value held$3.83M
Portfolio Weight2.67%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ACUTA CAPITAL PARTNERS, LLC's TSHA position evolved

ACUTA CAPITAL PARTNERS, LLC first disclosed a stake in TSHA in Q3 2023 at 3,827,926 shares (US$12.1M). Across 11 filings, ACUTA CAPITAL PARTNERS, LLC increased the stake 1 time(s), trimmed it 7 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 561,808 shares valued at US$3.8M — an increase of 122,344 shares quarter over quarter.. Notable position changes include a 30% trim in Q2 2024 (shares fell 10% over the following quarter), a 58% trim in Q4 2024 (shares fell 20% over the following quarter), a 28% increase in Q2 2026 (shares fell 28% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.83M $12.10M New
Q4 2023 3.59M $6.35M Reduce
Q1 2024 3.33M $9.57M Reduce
Q2 2024 2.33M $5.22M Reduce
Q3 2024 2.12M $4.26M Reduce
Q4 2024 884.24K $1.53M Reduce
Q2 2025 485.67K $1.12M New
Q3 2025 454.83K $1.49M Reduce
Q4 2025 454.83K $2.50M Hold
Q1 2026 439.46K $1.96M Reduce
Q2 2026 561.81K $3.83M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TSHA and 13F data

TSHA (TAYSHA GENE THERAPIES INC) is a Health Care company. 57 other funds we track also report a position in TSHA — the largest reported positions include Avoro Capital Advisors LLC (US$162.7M), RA CAPITAL MANAGEMENT, L.P. (US$160.4M), Vestal Point Capital, LP (US$132.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TSHA

All TSHA fund holders →

FAQ

How long has ACUTA CAPITAL PARTNERS, LLC held TSHA?

ACUTA CAPITAL PARTNERS, LLC has disclosed TSHA holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

What is ACUTA CAPITAL PARTNERS, LLC's current position in TSHA?

As of Q2 2026, ACUTA CAPITAL PARTNERS, LLC holds 561.81K shares of TSHA (TAYSHA GENE THERAPIES INC), valued at $3.83M, representing 2.67% of its reported portfolio and ranking #15.

Has ACUTA CAPITAL PARTNERS, LLC been buying or selling TSHA?

In the latest 13F filing (Q2 2026), ACUTA CAPITAL PARTNERS, LLC increased its position in TSHA.

Which other funds hold TSHA?

Other major institutional holders of TSHA include Avoro Capital Advisors LLC, RA CAPITAL MANAGEMENT, L.P., Vestal Point Capital, LP, among 57 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.